Barr: PharmaVitae Generics Profile

Content

• Chapter 1 Executive Summary
  • Key findings
  • Historical ethical sales performance
  • Therapeutic focus
  • Branded and generic drug outlook, 2006-12
  • Generic drug launch history
  • SWOT analysis
  • Strengths
  • Weaknesses
  • Opportunities
  • Threats
• Chapter 2 Corporate History
  • Key findings
  • Background
  • Key corporate developments
  • M&A history
  • Pliva acquisition
  • M&A strategy
  • Deals and alliances
  • Current corporate structure
  • Current management team
• Chapter 3 Historical Performance
  • Key findings
  • Introduction
  • Revenue and growth rate analysis, 2001-06
  • Revenue and growth rate versus generic peer set
  • Product analysis, 2002-06
  • Growth drivers
  • Growth resistors
  • Operating revenue and cost analysis, 2002-06
  • Operating revenue/cost analysis
• Chapter 4 Brand Forecast Performance
  • Key findings
  • Overview
  • Branded growth drivers
  • Seasonale
  • ParaGard
  • Cenestin
  • Katadolon
  • 2006 launches
  • Branded pipeline
• Chapter 5 Key Products and Competitors
  • Key findings
  • Overview
  • Therapy area focus, 2002-06
  • Branded portfolio
  • Generic portfolio
  • Generic and biosimilar products
  • Oral contraceptives
  • Warfarin
  • Desmopressin
  • Azithromycin
  • Generic outlook
  • Biosimilar pipeline
• Chapter 6 Appendix
  • IMS versus company-reported data reconciliation
  • References
  • Abbreviations
  • Exchange rates
• List of Tables
  • Table 1: Barr's product licensing agreements, 2000-06
  • Table 2: Barr's corporate executive committee, 2007
  • Table 3: Generic peer set overview, 2006
  • Table 4: Barr's operating revenue/cost analysis ($m), 2002-06
  • Table 5: Barr's operating cost ratio analysis (% of total revenues), 2002-06
  • Table 6: Barr's branded products with 2006 approval/launch
  • Table 7: Barr's key generic product overview, seven major market sales ($m), 2006
  • Table 8: Generic drugs launched by Barr in the US, fiscal year 2006
  • Table 9: Barr's generic pipeline in the US, 2006
  • Table 10: Exchange rates, 2006
• List of Figures
  • Figure 1: Historical ethical (generic and brand) global sales performance for Barr and generic pharma peer set (% CAGR), 2002-06
  • Figure 2: Barr's generic therapeutic focus versus generic pharma peer set (%), 2006
  • Figure 3: Barr's branded and generic drug forecast, 2006-12
  • Figure 4: Percentage revenues attributed to generics launched in the US by Barr and its peer set, 2002-06
  • Figure 5: Barr - SWOT analysis, 2007
  • Figure 6: Barr's M&A history, 2001-06
  • Figure 7: Barr's corporate structure, 2007
  • Figure 8: Barr's global ethical sales revenue and growth rate, ($m), 2001-06
  • Figure 9: Barr's total global ethical revenue and growth rate compared to generic peer set, 2001-06
  • Figure 10: Barr's growth drivers/resistors of historical revenue performance ($m), 2002-06
  • Figure 11: Barr- operating revenue/cost analysis ($ billion), 2002-06
  • Figure 12: Barr's operating cost ratio analysis (% of total revenues), 2002-06
  • Figure 13: Barr's operating cost ratio versus peer set (%), 2006
  • Figure 14: Barr's branded growth drivers, 2006
  • Figure 15: Barr's top seven products, seven major market sales ($m), 2006
  • Figure 16: Barr's branded sales by therapeutic class, 2006
  • Figure 17: Barr's generic sales by therapeutic class, 2006
  • Figure 18: IMS versus company-reported ethical sales discrepancy ($m), 2006